Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Total Non-Current Liabilities (2016 - 2025)

Dare Bioscience (DARE) has disclosed Total Non-Current Liabilities for 11 consecutive years, with $22.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities rose 50.6% year-over-year to $22.7 million, compared with a TTM value of $22.7 million through Sep 2025, up 50.6%, and an annual FY2024 reading of $23.4 million, up 4.24% over the prior year.
  • Total Non-Current Liabilities was $22.7 million for Q3 2025 at Dare Bioscience, up from $20.8 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $32.7 million in Q4 2022 and bottomed at $6.1 million in Q2 2021.
  • Average Total Non-Current Liabilities over 5 years is $20.0 million, with a median of $20.8 million recorded in 2025.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 96.9% in 2021, then plummeted 31.48% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $17.1 million in 2021, then skyrocketed by 91.84% to $32.7 million in 2022, then tumbled by 31.48% to $22.4 million in 2023, then increased by 4.24% to $23.4 million in 2024, then dropped by 2.98% to $22.7 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for DARE at $22.7 million in Q3 2025, $20.8 million in Q2 2025, and $23.4 million in Q1 2025.